Collaborators
Sign in to add collaborator| Sima Lev | collaborator | Oregon State University - OHSU | |
| Sima Lev | collaborator | OHSU |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mohanty V, Baran N, Huang Y, et al. (2024) Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML. Biorxiv : the Preprint Server For Biology |
| Saridogan T, Akcakanat A, Zhao M, et al. (2023) Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Scientific Reports. 13: 20223 |
| Kinose Y, Xu H, Kim H, et al. (2023) Dual blockade of BRD4 and ATR/WEE1 pathways exploits loss in clear cell ovarian cancer. Research Square |
| Doha ZO, Wang X, Calistri NL, et al. (2023) MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer. Nature Communications. 14: 5665 |
| Park SY, Jeong KJ, Poire A, et al. (2023) Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer. Cell Death & Disease. 14: 532 |
| Lenz L, Neff C, Solimeno C, et al. (2023) Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes. Breast Cancer Research and Treatment |
| Lei JT, Jaehnig EJ, Smith H, et al. (2023) The Breast Cancer Proteome and Precision Oncology. Cold Spring Harbor Perspectives in Medicine |
| Park KC, Kim JM, Kim SY, et al. (2023) PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models. Bmc Medicine. 21: 38 |
| Tatarova Z, Blumberg DC, Bensen A, et al. (2023) Panobinostat Induced Spatial In Situ Biomarkers Predictive of Anti-PD-1 Efficacy in Mouse Mammary Carcinoma. Cells. 12 |
| Yan G, Luna A, Wang H, et al. (2022) BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer. Cell Reports. 40: 111304 |